Latest Safety News

Page 2 of 252
Actinogen Medical’s shares have been suspended while it completes analysis of additional data from its pivotal XanaMIA Alzheimer’s trial. The company expects trading to resume no later than 19 November unless the results announcement comes first.
Ada Torres
Ada Torres
17 Nov 2026
Island Pharmaceuticals is moving Galidesivir into a decisive sequence of Marburg animal studies after the FDA confirmed an Animal Rule pathway for the antiviral. The company also expects to generate prospective human data through an approved Uganda Ebola program, although approval, funding and commercial outcomes remain unresolved.
Victor Sage
Victor Sage
17 Nov 2026
AdAlta has taken ownership of the US FDA Orphan Drug Designation for EW-001, strengthening the commercial case for its mesothelioma CAR-T therapy. The designation follows a constructive pre-IND meeting, but approval and clinical success remain unproven.
Ada Torres
Ada Torres
17 Nov 2026
Mastermyne Group Limited (ASX:MYE) has set FY27 revenue guidance of $305 million to $320 million and underlying EBITDA guidance of $28.5 million to $31.5 million after new contracts more than doubled its order book to approximately $834 million. The mining services group is also assessing expansion into surface mining and other adjacent markets.
Maxwell Dee
Maxwell Dee
16 Nov 2026
Vectus Biosystems has received supportive written FDA feedback on VB0004, reducing uncertainty around the drug candidate’s manufacturing, nonclinical and planned clinical development package. The company will now incorporate the guidance into an IND application for a Phase Ib/IIa study in IPF patients in Australia.
Ada Torres
Ada Torres
16 Nov 2026
ClearVue Technologies has secured a letter of award for solar cladding on a government-owned building in Singapore, with the subcontract valued at up to A$859,000. The project gives the company a sizeable regional reference site, although the award remains subject to final design, scope and manufacturing approvals.
Victor Sage
Victor Sage
16 Nov 2026
Neurizon’s first participant in the 250-person Regimen I ALS trial has completed the 36-week randomised phase and entered an optional active treatment extension. The milestone keeps the program on track for topline results in late Q2 2027, while recent FDA feedback points to a potential single-trial approval pathway if the data meet regulatory standards.
Ada Torres
Ada Torres
13 Nov 2026
Bass Oil delivered a stronger October, with group production up 28% to 13,146 barrels and revenue rising 8.3% to A$1.83 million. Bunian 6 is exceeding expectations, while Vanessa remains on track for first gas sales by year end, subject to approvals and remaining site work.
Maxwell Dee
Maxwell Dee
13 Nov 2026
Cynata Therapeutics has lifted its proposed shareholder-approved placement to approximately $750,000, taking potential proceeds from its two-stage capital raising to about $1.663 million before costs. The biotech says key clinical and termination costs have been paid, while its externally funded kidney transplant trial remains in follow-up.
Ada Torres
Ada Torres
13 Nov 2026
Etherstack has secured a US$1.8 million expansion to its primary project with an unnamed Tier 1 US telecommunications carrier. Most of the additional revenue is expected to be recognised within 90 days, spanning FY26 and FY27.
Sophie Babbage
Sophie Babbage
12 Nov 2026
Miro Sciences says Australia’s medicines regulator has completed its inspection of the manufacturing site for StemSmart, supporting the company’s planned Phase 2 Crohn’s disease trial. The inspection is a significant readiness step, but it is not itself approval to begin the study or confirmation of a successful audit outcome.
Ada Torres
Ada Torres
12 Nov 2026
Macallum New Energy has begun well design and regulatory work for three potential exploration wells in Western Australia’s EP 494 permit. The programme remains conditional on securing a farm-out partner, with final target selection and a potential investment decision expected in Q1 2027.
Victor Sage
Victor Sage
12 Nov 2026

Browse the archive

Full archive